Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
"How NRx Could Upend the Fight Against Depression and Suicide"
RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit http://www.nrxpharma.com.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL03022&sd=2024-09-11 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html
SOURCE NRx Pharmaceuticals, Inc.
That’s exciting news about Metavesco and Local Choice Spirits teaming up for a limited-edition bourbon! Launching it at the historic Striped Pig Distillery sounds like a perfect blend of tradition and innovation. It’s kind of like how nih federal credit union customer service consistently delivers a reliable experience, especially in shifting market conditions. Always great to see creative ventures adapt and thrive! Looking forward to seeing how this project turns out.
$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series
CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.
In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.
“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”
Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.
Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”
The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.
About Metavesco
Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.
About Local Choice and Striped Pig Distillery
The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.
Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405
For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/
Safe Harbor Statement
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.
CONTACT:
info@metavesco.com
(678) 341-5898
$MVCO @Metavesco executes letter of intent to acquire Striped Pig Distillery and Local Choice Spirits
Click here for story:
https://seekingalpha.com/news/4141201-metavesco-executes-letter-of-intent-to-acquire-striped-pig-distillery-and-local-choice-spirits
$YGMZ Investor Overview: https://ir.szygmz.com/investor-overview/
About MingZhu Logistics Holdings Limited (Nasdaq: YGMZ)
Established in 2002 and headquartered in Shenzhen, China, MingZhu Logistics Holdings Limited is a 4A-rated professional trucking service provider. Based on the Company's regional logistics terminals in Guangdong Province, MingZhu Logistics Holdings offers tailored solutions to our clients to deliver their goods through our network density and broad geographic coverage across the country by a combination of self-owned fleets tractors and trailers and subcontractors' fleets.
For more information, please visit https://ir.szygmz.com/.
$BHAT - Unlike traditional gold companies, Blue Hat is not merely a gold trader earning from the buy-sell spread; rather, it will generate revenue from various aspects of the gold supply chain. Additionally, Blue Hat's gold sources are not limited to newly mined gold but also include gold that recycle from market consumers.
https://www.globenewswire.com/en/news-release/2024/08/15/2930903/0/en/Blue-Hat-Expands-into-Gold-Trading-with-Strategic-Partnerships-As-Gold-Prices-Rise-Amid-Economic-Optimism.html
$IDVV News: Corporate Update
CARLSBAD, CA, August 1, 2024 (OTCMARKETS) -- International Endeavors Corp. ("IEC") (OTC PINK: IDVV), a technology holdings company announced the following statement.
The company WITech division has finalized its agreement to launch Winners Waygers an AI (Artificial intelligence) based sports handicapping service developed an to assist with picking winners, research, and odds management for fantasy leagues, and professional sports handicapping (NFL, NBA, UFC, MLB, MLS) and Horse betting.
Currently the service is being used by professional handicappers and WITech plans to bring the service mainstream beginning with the NFL Season, then expanding it out to other mainstream sports. A slow launch is necessary due to the complexity that only professional handicappers can understand. We want to make the service very simple and easy to use as we roll it out mainstream.
We are planning to launch in phases. Starting with a limited time only free beta site by August 15th that will allow users to sign up for NFL picks, combined with data and research. Following phases we anticipate rolling out in Q4 will begin to combine additional sports and a generative AI bot that will allow paying members to ask handicapping questions and receive data to assist the in making bets.
To address the questions about the July release. Our initial plans were to begin the launch in July, but we had to secure portions of the backend of the website as portions of the backend were corrupted by persons trying to scrape data from the site. We discovered the breach, and have since repaired the issue.
We are launching and we see a massive opportunity for a subscription-based model.
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone:833-705-0022
Email:otc@idvvcorp.com
SOURCE:
International Endeavors Corporation, Inc.
IGPK... THIS IS HUGE : Jun Fenghuang Group Experiencing Rapid Growth and Expansion... -- https://finance.yahoo.com/news/jun-fenghuang-group-experiencing-rapid-140000992.html
This is huge coming from the company:
The company is committed to consolidating all its divisions under one Jun Fenghuang Group, currently represented by the publicly traded OTC markets ticker IGPK, until the ticker is formally changed to JFHE.
JFH Digital E-Commerce Co., LTD is dedicated to listing on NASDAQ upon completing the merger of all its divisions.
Waiting on the name and symbol ticker to JFHE .......
Up 51% today because of NEWS PR released
AFFL will explode to $105.3768, $18.3515, and $16.568 respectively based on its two peer's MV at peak and its Record-High MV!
LOL, even buying its OTC peer (FCCN: Record-High $41.3) at today's high $5.15 = buying AFFL at $13.1402 which is 404.314 Times of current Super-Ridiculous-Low price $0.0325! Which means Easy 404-Bagger Giant & Quick Rally here!
LOL, even buying its OTC-CI-tier peer (SSHT: Record-High $4.1) at June's High $0.95 = buying AFFL at $4.2522 which is 130.84 Times of current Super-Ridiculous-Low price $0.0325! Which means Easy 130-Bagger Giant & Quick Rally here! Note, SSHT has -$54,256 Deeper Negative Net Asset or Shareholder's Equity Value v.s. AFFL only has -$33,935 Minor Negative Net Asset or Shareholder's Equity Value!
So, AFFL is Super Undervalued now!
AFFL is the Cheapest CLEAN-Shell with the Sought-After FIXED Super Tiny SS and Debt-FREE Excellent Financial Balance Sheet plus Only A Few Millions Shares Minor Float Available For Trading! Which means that this Diamond-In-Rough can Easily and Quickly soar Over 100-Bagger from here with just about A Couple Of Millions shares of Slapping-Volumes...
AFFL is also at Hyper Oversold status based on its Record-High $6.00!
Note, its recent high was $0.089!
$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year.
This has been pre-announced in the last two IVDN news releases:
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
$IFUS News July 08, 2024
Impact Fusion International Inc.: Louisiana State Legislature Unanimously Passes LA HCR-42 Focusing on Bagasse Utilization
https://finance.yahoo.com/news/impact-fusion-international-inc-louisiana-131500558.html
$AGBA News July 05, 2024
AGBA Group, one of Nasdaq’s top 10 best-performing stocks for 2024, further cements strategic partnership with Yorkville
https://finance.yahoo.com/news/agba-group-one-nasdaq-top-130000537.html
$CATV News: Category V Biotech, Inc. Announces Exclusive Licensing of Genetic Networks' Intellectual Property for Cannabis Applications
FLORIDA, July 2, 2024 – Category V Biotech, Inc. (OTC: CATV), formerly known as 4Cable TV International, Inc., is pleased to announce significant progress in our relationship with Genetic Networks, LLC (https://geneticnetworks.com/).
While continuing to analyze the acquisition, Category V Biotech and Genetic Networks have agreed to allow CATV to become the exclusive licensee of all Genetic Networks’ intellectual property and technology worldwide for cannabis applications. This agreement allows Genetic Networks time to address internal matters found during due diligence, while Category V Biotech begins its journey into the discovery of medicines using cannabis. This licensing agreement will facilitate close collaboration with Genetic Networks on cannabis research and development, positioning Category V Biotech as a leader in developing cannabis medicines.
Our goal is to screen cannabis and cannabis-derived products to determine their medicinal benefits by utilizing Genetic Networks' extensive disease database accumulated over the past decade while working for pharmaceutical companies and government. Discovering the use of cannabis for specific diseases is key to developing medicines that can be registered with regulatory bodies worldwide and distributed for medical use or treatment.
The exclusive licensing of Genetic Networks’ technologies, including their proprietary platform GeneScape™, will facilitate the rapid and unbiased discovery of optimal drug compounds from cannabis through whole-genome analysis. This exclusive license allows Category V Biotech to expand into the biotech sector of the cannabis industry, leveraging Genetic Networks' expertise in accelerating compound discovery and development for pre-clinical and clinical testing.
"We are excited to welcome Genetic Networks into the Category V Biotech family," stated Michael Feldenkrais, CEO of Category V Biotech. "Their state-of-the-art platform and extensive knowledge will be instrumental as we strive to unlock the full potential of cannabis-based therapeutics. Together, we anticipate bringing novel treatments to patients faster than ever before, as regulated FDA products under the new regulatory environment of the United States." Dr. Gennaro D’Urso, co-founder of Genetic Networks, echoed this enthusiasm, stating, "Category V Biotech shares our dedication to leveraging genetics to revolutionize drug development. By joining forces, we envisage broadening the reach and impact of our platform, ultimately delivering superior medicines to patients in need."
Upon resolving internal matters identified during due diligence, Category V Biotech will complete the acquisition of Genetic Networks. Following the transaction, Genetic Networks will operate as a wholly owned subsidiary of Category V Biotech, retaining its existing management team and facilities. Category V Biotech plans to leverage Genetic Networks' capabilities across its global cannabis operations, including cultivation, biotech research, and retail. This transaction culminates years of discussions, awaiting the right moment for research and development in the United States to create pharmaceutical-grade products using cannabis.
The recent changes in the rescheduling of cannabis from Controlled Substance I to Controlled Substance III, reflecting a change in U.S. policies, has paved the way for Category V Biotech and Genetic Networks to capitalize on emerging opportunities in the cannabis industry, driving innovation and advancing therapeutic solutions for patients. Category V Biotech remains actively engaged in pursuing additional acquisitions in the cannabis industry as part of its growth strategy, with further transactions expected to be announced in the coming months.
About Genetic Networks, LLC
Established in 2015, Genetic Networks, LLC has been at the forefront of serving three of the top ten bio-pharmaceutical companies with its GeneScape™ technology. GeneScape™ expedites drug asset development through applied molecular biology, offering a multidimensional map of diseases and drugs that integrates genome-wide functional assays of drug activity (H-Tech) and human genes and gene variants (Y-Tech) using proprietary analytics. Genetic Networks' GeneScape™ platform accelerates the discovery and development of optimal candidate compounds for pre-clinical and clinical testing, identifying the optimal intersection between targets and compounds in specific disease spaces through whole-genome genetic perturbation and analysis. About Category V Biotech, Inc. Category V Biotech, Inc. (OTC: CATV) aims to establish and operate a fully integrated global cannabis company, encompassing biotech research, cultivation, manufacturing, and retail. Through strategic acquisitions and organic growth, the company strives to emerge as the world's leading provider of pharmaceutical cannabis-based products and therapies.
$AGBA - Mr. Wing-Fai Ng, Group President of AGBA Group Holding Limited stated, “Our team is working in overdrive in creating Triller’s next-generation social media and entertainment ecosystem for creators and users. We believe our next generation of offerings will establish a new standard in the industry.
https://finance.yahoo.com/news/agba-triller-4bn-merger-group-122000311.html
$AVRW Seratopical skin care products are keeping the famous Nicole Kidman looking her best. Everyone can clearly see this.
When it comes to anti-aging skincare, Kidman's loyalty lies with Seralabs. Kidman, who has been working with the brand since 2020, told InStyle that she “loves using Seratopical because it makes my skin smooth and hydrated.” In honor of the brand ambassador’s birthday, Seralabs is offering 30 percent off sitewide all week with the code NK30.
LINK:
https://www.instyle.com/nicole-kidman-birthday-favorite-beauty-products-8666305?utm_source=twitter&utm_medium=social&utm_campaign=shareurlbuttons
$SFWJ - announces a new strategic partnership with one of its subsidiaries with a prominent local Colombian company to begin the export of its first crop of CBD buds to Switzerland within the next six months.
https://finance.yahoo.com/news/sfwj-medcana-announces-strategic-partnership-134500645.html
Mean historical return and volatility for a 25 blue chips for long-term and short-term time intervals.
As all of you know, the historical expected return and volatility of stock is a very important characteristics of the stock stability and profitability. Here is the comparison of these values for 25 blue chips for two historical data intervals, 11 years and 1 month. 11 years interval shows long-term
stock price tendencies, and 1 month interval exhibits stock price tendency in the near past.
This is a table for 25 blue chips and their expected return and volatility for 11 years of the historical data from 2013-01-02 to 2024-06-13 ordered by the expected return.
symbol
expected return
volatility
MSFT
0.274
0.266
AAPL
0.233
0.283
UNH
0.213
0.25
MA
0.209
0.262
NOC
0.173
0.234
HD
0.16
0.234
LMT
0.149
0.216
ABBV
0.146
0.264
JPM
0.137
0.261
ORCL
0.13
0.264
KR
0.125
0.273
AXP
0.123
0.293
NKE
0.119
0.279
CAT
0.116
0.283
GS
0.113
0.274
HON
0.112
0.219
MRK
0.109
0.209
SBUX
0.098
0.258
WMT
0.097
0.201
MCD
0.095
0.194
PG
0.08
0.18
JNJ
0.065
0.175
KO
0.046
0.176
INTC
0.031
0.32
CVX
0.029
0.281
As you can see, the leader of the table is the Microsoft stocks with their 0.274 yearly expected return and 0.266 volatility.
The next table is the same one, but for the last month of the data, from 2024-05-14 to 2024-06-14 ordered by the expected return.
symbol
expected return
volatility
ORCL
3.613
0.512
AAPL
3.21
0.294
WMT
2.648
0.266
MSFT
1.001
0.177
SBUX
0.81
0.279
ABBV
0.625
0.213
HON
0.344
0.149
HD
0.235
0.219
NKE
0.077
0.163
MRK
0.075
0.174
PG
0.074
0.136
KO
-0.095
0.113
LMT
-0.197
0.144
INTC
-0.2
0.272
MA
-0.216
0.105
GS
-0.262
0.171
UNH
-0.316
0.224
JPM
-0.361
0.243
JNJ
-0.363
0.174
MCD
-0.526
0.198
CVX
-0.551
0.183
AXP
-0.56
0.17
KR
-0.655
0.124
CAT
-0.71
0.184
NOC
-0.721
0.141
As you can see, the leader of the table for one month is the Oracle stocks with their prominent 3.613 yearly expected return and 0.512 volatility. It means that the Oracle stock prices for the last month raised quite steadily.
And finally, here is the performance of the portfolio consisted of these blue chips.
Optimization were performed by maximization of the Sharpe ratio, for 11 years of historical data.
expected return
0.224
volatility
0.188
Sharpe ratio
1.063
Allocation sum
10000.00
Leftover
128.49
All the calculations were made with the help of the website for portfolio optimization
https://asset-master.net/
The recommended browser is Firefox.
Welcome to discuss!
$FAVO News May 22, 2024
FAVO Capital & Stewards Investment Capital Win Prestigious Global Finance Award
https://finance.yahoo.com/news/favo-capital-stewards-investment-capital-130500781.html
$RENB: Impressive Short Squeeze Triggered for Cancer Immunotherapy Company Renovaro, Inc. (NASDAQ: RENB)
https://markets.financialcontent.com/startribune/article/getnews-2024-6-10-impressive-short-squeeze-triggered-for-cancer-immunotherapy-company-renovaro-inc-nasdaq-renb
$AVRW News: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results
New Initiatives Showing Encouraging Results
SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.
Key financial highlights for the fourth quarter included the following:
Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.
Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.
Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.
Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.
Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.
"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.
Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.
Operational Highlights
Other operational highlights during the fourth quarter of 2023 included:
Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/
About Avenir Wellness Solutions, Inc.
Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: www.avenirwellness.com.
About The Sera Labs, Inc.
Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
CONTACTS:
Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com
SOURCE: Avenir Wellness Solutions, Inc. (f/k/a Cure Pharmaceutical Holding Corp.)
$FAVO - Global Finance's eleventh annual Innovators Awards program celebrates entities across various categories, including banks, companies, and fintechs, that consistently pioneer new paths and develop innovative financial tools.
https://finance.yahoo.com/news/favo-capital-stewards-investment-capital-130500781.html
Mean historical return and volatility for a 25 blue chips for long-term and short-term time intervals.
As all of you know, the historical expected return and volatility of stock is a very important characteristics of the stock stability and profitability. Here is the comparison of these values for 25 blue chips for two historical data intervals, 11 years and 1 month. 11 years interval shows long-term
stock price tendencies, and 1 month interval exhibits stock price tendency in the near past.
This is a table for 25 blue chips and their expected return and volatility for 11 years of the data from 2013-01-02 to 2024-05-17.
symbol
expected return
volatility
AAPL
0.221
0.282
ABBV
0.147
0.265
AXP
0.133
0.293
CAT
0.125
0.283
CVX
0.035
0.282
GS
0.118
0.274
HD
0.16
0.235
HON
0.112
0.219
INTC
0.036
0.32
JNJ
0.071
0.175
JPM
0.143
0.261
KO
0.047
0.176
KR
0.132
0.274
LMT
0.152
0.216
MA
0.214
0.263
MCD
0.102
0.194
MRK
0.112
0.209
MSFT
0.271
0.267
NKE
0.118
0.279
NOC
0.185
0.235
ORCL
0.118
0.261
PG
0.081
0.18
SBUX
0.096
0.258
UNH
0.22
0.25
WMT
0.095
0.201
As you can see, the leader of the table is the Apple stocks with their 0.221 yearly expected return
and 0.282 volatility.
The next table is the same one, but for the last month of the data, from 2024-04-17 to 2024-05-17.
symbol
expected return
volatility
AAPL
3.062
0.258
ABBV
0.162
0.21
AXP
2.499
0.268
CAT
-0.064
0.346
CVX
0.569
0.172
GS
4.366
0.165
HD
0.47
0.191
HON
1.466
0.121
INTC
-0.73
0.39
JNJ
1.129
0.192
JPM
3.362
0.137
KO
1.345
0.096
KR
-0.199
0.159
LMT
0.287
0.11
MA
0.003
0.134
MCD
0.108
0.139
MRK
0.682
0.166
MSFT
0.259
0.229
NKE
-0.278
0.193
NOC
0.571
0.19
ORCL
0.579
0.217
PG
1.126
0.084
SBUX
-0.689
0.583
UNH
1.836
0.177
WMT
1.514
0.271
As you can see, the leader of the table for one month is still the Apple stocks with their prominent 3.062 yearly expected return and 0.258 volatility. It means that the AAPL stock prices for the last month raised quite steadily.
And finally, here is the performance of the portfolio consisted of these blue chips.
Optimization were performed by maximization of the Sharpe ratio, for 11 years of historical data.
expected return of the portfolio
0.223
volatility
0.184
Sharpe ratio
1.076
All the calculations were made with the help of the website for portfolio optimization
https://asset-master.net/
The recommended browser is Firefox.
Welcome to discuss!
$ACGX: Profitable Holding Company with Multi-Million Dollar Real Estate Holding plus SAAS Lifestyle Hospitality Firm: OTC: ACGX https://apnews.com/press-release/ein-presswire-newsmatics/hospitality-and-leisure-industry-real-estate-7ac93481029344c4df7052d7063f9a61
IGPK.... Yield is GONE. 🚀🚀. Today the yield sign is gone!!! This week Dark defunct was removed, Grace period removed , Annual Report filed, Attorney letter, updated attorney letter. ... The 1st quarter will be filed any moment now... today would be best time to grab some shares before the quarterly is filed...
$AGBA Article May 08, 2024
Triller CEO says deal with Bob Diamond-backed AGBA will revitalize social media push
https://www.axios.com/pro/media-deals/2024/05/08/triller-ceo-says-deal-with-bob-diamond-backed-agba-will-revitalize-social-media-push
IGPK ... huge name change finally done. This is from Nevada Secretary of State: Name change
Name :JFH DIGITAL E-COMMERCE CORP.
Entity Type :Domestic Corporation (78)Jurisdiction :Nevada
Formation Date in Jurisdiction :
Annual Report Due Date :12/31/2024
$AGBA - Mr. Wing-Fai Ng, Group President of AGBA Group Holding Limited said “Creating shareholder value is not a throwaway line at AGBA. We single-mindedly focus on it. Our colleagues and I are proud shareholders in our exceptional company. We are deeply grateful and highly energized by the overwhelmingly positive response to our $4 billion merger with Triller. We are all excited about working non-stop to seize this 'once-in-a-generation' opportunity.”
https://finance.yahoo.com/news/empowering-shareholders-agbas-us-4b-130000814.html
20 BILLION A/S and 6 BILLION O/S.
Current PPS .0001
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174350000
Looks like that post was spot on.
Paradigm Oil and Gas, Inc. ( OTCBB: $PDGO ), a leading energy company, is thrilled to announce the successful acquisition of a 100% interest in 58 oil and gas wells along with 600 acres of land in Oklahoma.
https://www.otcmarkets.com/stock/PDGO/news/PDGO-Announces-Acquisition?id=436678
$NCL News: Northann Corp Enters Strategic Relationship with Rexil Group of Companies Netherlands to Promote Sustainable Technology and Products
ELK GROVE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Northann Corp (NYSE American: NCL), a leading innovator in 3D-printed home improvement solutions, is pleased to announce the signing of a strategic relationship with Golden Gate BCE B.V., a subsidiary of Rexil Group of Companies Netherlands, a prominent distributor in the Netherlands. This collaboration aims to enhance the presence of sustainable technology and products throughout Rexil Group of Companies Netherlands and its subsidiaries distribution channels.
Under this agreement, Rexil Group of Companies Netherlands will promote Northann Corp's environmentally friendly products, Blue11 and SuperOak, to its extensive network of customers in the Netherlands. This partnership aligns with Northann Corp's commitment to sustainability and innovation, furthering its mission to transform spaces through cutting-edge solutions.
"We are thrilled to partner with Rexil Group of Companies Netherlands to bring our sustainable technology and products to a wider audience in the Netherlands," said Lin Li, CEO and President of Northann Corp. "This collaboration underscores our dedication to environmental stewardship and showcases our commitment to providing innovative solutions to our customers."
Northann Corp’s partnership with Rexil Group of Companies Netherlands represents a significant step forward for the Company in its efforts to expand its global presence and promote sustainable practices within the industry. Both companies share a common vision for driving positive change through innovation and sustainability, making this a synergistic collaboration for both parties.
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit www.northann.com.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
$AGBA Merger - An Overview Of Triller$AGBA - An Overview Of Triller
Triller is a pioneering force in the intersection of technology, entertainment, and commerce, leveraging advanced AI to drive user engagement and content monetization.
▪ Comprehensive digital content and technology platform that caters to creators, brands, and consumers across a global scale.
▪ Recognized for its broad appeal, demonstrated by its significant user base, which includes well-known creators like Charli D’Amelio, Marshmello, Bryce Hall, Jennifer Lopez, Eminem, Da Baby and The Weeknd.
Building the world’s largest space for creators to create, distribute and monetize content
Triller is a pioneering force in the intersection of technology, entertainment, and commerce, leveraging advanced AI to drive user engagement and content monetization.
▪ Comprehensive digital content and technology platform that caters to creators, brands, and consumers across a global scale.
▪ Recognized for its broad appeal, demonstrated by its significant user base, which includes well-known creators like Charli D’Amelio, Marshmello, Bryce Hall, Jennifer Lopez, Eminem, Da Baby and The Weeknd.
Building the world’s largest space for creators to create, distribute and monetize content
$CBDL - "We have nearly completed the rebranding and are extremely excited about the upcoming launch, which we expect to announce by mid-May 2024."
https://finance.yahoo.com/news/cbd-life-sciences-provides-exciting-120000086.html
IGPK.... This might be the last day to buy at this stock price... Name change, drop yield sign, change info , attorneys letter will update OTC, Filings for annual and 1st Quarter... What do you think this will be worth today? LMAO Oh yea, the merger FINs filing should show REVs in the millions of millions or about a BILLION..
TheStockGuru
@Austria_9999
$IGPK : JFHE
Phase - 1 second part will be fill soon. EXPECTING otc 2023 annual and first quarter 2024 report will upload in disclosure, Attorney letter will updated, Business description and insiders name Changes and yield sign will remove Today end of the day or Tomorrow!!!!!
12:17 PM · Apr 23, 2024
876 Views
$PDGO News April 15, 2024
PDGO Announces Acquisition
https://www.otcmarkets.com/stock/PDGO/news/PDGO-Announces-Acquisition?id=436678
$IVDN (16 million float) News on Rising Sales of Superior Insulation Product: Innovative Designs Vendor Growth
PITTSBURGH, PA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovative Designs, Inc. (OTCQB: IVDN) continues to gain market share through its growing vendor base. Since the beginning of this fiscal year (November 1, 2023), Innovative Designs has added over 30 new accounts that have purchased its Insultex House Wrap®. This has resulted in a comp sales increase of 318% as compared to the same time period last year (November 2022 – April 2023). With 7 months remaining in FY2024, sales for the first 5 months are approaching 88% of last year's total.
Randy Kimbler, a National Distributor of Insultex, commented, “The introduction of Insultex® House Wrap to several major building supply companies has been very well-received. The product is being placed in the retail locations of these organizations, as well as many local building supply companies. The R-6 insulation value provided by this very thin product has proven to be an affordable solution for builders facing economic challenges in states where energy codes require R-5 Continuous insulation for new construction.”
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
Website: http://www.insultexhousewrap.com
Link: https://finance.yahoo.com/news/innovative-designs-vendor-growth-173800119.html
$AGBA News February 15, 2024
AGBA Celebrates Major Milestone with Successful Completion of Private Placement at a Premium to Market Price
https://finance.yahoo.com/news/agba-celebrates-major-milestone-successful-140000317.html
Looking forward to hearing more about the rollout of the amusement parks in Indonesia. $GDHG
$GDHG -Our diverse portfolio spans six successful amusement parks across #China, strengthened with our recently announced collaboration agreements & our exciting venture to launch 30 - 50 indoor amusement parks in #Indonesia See our recent #press https://ir.jsyoule.com $DIS $GDHG
GDHG -Our diverse portfolio spans six successful amusement parks across #China, strengthened with our recently announced collaboration agreements & our exciting venture to launch 30 - 50 indoor amusement parks in #Indonesia See our recent #press https://t.co/fhEm1O5pmT $DIS $GDHG pic.twitter.com/ois3YUdCNf
— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 4, 2024
$IQST - iQSTEL $1 billion revenue on the horizon! QXTEL deal adds $80M sales!
https://marketsherald.com/iqstel-inc-s-accelerated-path-to-1-billion-a-study-in-strategic-growth/
$PDGO - In connection with the previously announced change in control, the new management of PDGO has commenced the process of identifying and initiating targeted acquisitions for PDGO.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-and-Gas-Inc-announces-its-plans-going-forward?id=436241
$IQST is one of the best stocks to buy now in April 2024!
$AGBA News February 27, 2024
AGBA Group is Positioned For Hong Kong's Rebounding Macro Environment with Business Refinements and Growth Strategies
https://www.marketwatch.com/press-release/agba-group-is-positioned-for-hong-kong-s-rebounding-macro-environment-with-business-refinements-and-growth-strategies-f566e8f4
$SHOT News April 06, 2024
Safety Shot Full Year 2023 Earnings: US$0.48 loss per share (vs US$0.70 loss in FY 2022)
https://finance.yahoo.com/news/safety-shot-full-2023-earnings-130158250.html
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-123000217.html
$SHOT News April 08, 2024
$5 Million No Warrants Private Placement Reaffirms Investor Confidence In Safety Shot Inc. (NASDAQ: SHOT)
https://www.marketwatch.com/press-release/5-million-no-warrants-private-placement-reaffirms-investor-confidence-in-safety-shot-inc-nasdaq-shot-fbb40cd1
$PDGO News December 28, 2023
Paradigm Oil And Gas, Inc. Announces Change in Control and Letter of Intent
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-And-Gas-Inc-Announces-Change-in-Control-and-Letter-of-Intent?id=425854
$GTVH - This collaboration signifies the Company’s commitment to fostering further transparency and streamlined communication efforts to its shareholders.
https://finance.yahoo.com/news/golden-triangle-ventures-inc-forges-120000355.html
10x coming for SODE: Annual report and current filing: 1) unrestricted shares a measly 31M only 2) gross profit 3) no change in OS for years 4) no convertible debt...entry pps IMO...spike from under a cent to $1 pps in 2021; spike to 10 cent pps in 2022
https://www.otcmarkets.com/stock/SODE/disclosure
$NRXP News: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend
-- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per share improvement in negative earnings. Additions to working capital of $8 million in Q1 2024.
-- Company forecasts first commercial revenue in 2024 from sales of ketamine and related technologies. Company received advance of first milestone payments in 2024 for ongoing development of NRX-101 from Alvogen and Lotus Pharmaceuticals, Inc. (1975.TW)
-- Company announces new partnership around the first drug to potentially modify the underlying cause of schizophrenia
-- Data lock this week and top-line data expected this month, after completed enrollment of the Phase 2b/3 trial of NRX-101 in Treatment Resistant Bipolar Depression (TRBD); trial demonstrated 94% rater concordance, far in excess of industry norms and exceeded industry norms in medication compliance
-- Two new Investigational New Drug applications (INDs) accepted by the US Food and Drug Administration (FDA) for NRX-101 in Chronic Pain and Complicated UTI.
-- Data lock expected this week in 200-person DOD-funded trial of D-cycloserine (DCS), the key component of NRX-101, to treat chronic pain, conducted by Northwestern University
-- Grant of Qualified Infectious Disease Product (QIDP), Fast Track and Priority Review designations for NRX-101 in the treatment of Complicated Urinary Tract Infection (cUTI); Publication last week of QIDP-qualifying data in a peer-reviewed journal. NRx is reviewing partnership options
-- Established HOPE Therapeutics to develop and launch IV Ketamine together with related technologies with FDA New Drug Application to be submitted this year. In advance of FDA approval, HOPE is partnered with national 503b and 503a pharmacies to address the ketamine shortage declared by FDA. HOPE is planned to be spun out as a separate company to be owned by NRx, current NRx shareholders via a tax-free dividend, and new investors; Term Sheets received from prospective anchor investors for $60 million of new investment, once publicly listed
-- HOPE is presenting data from four randomized, prospective trials demonstrating safety and efficacy in 800 patients of IV Ketamine in treating severe and suicidal depression as the clinical basis for New Drug Application (NDA) for HTX-100 (IV Ketamine); expecting stability and CMC data sufficient for NDA filing by June 2024.
-- Added over $8 million in working capital, including an advance of a $5.1 million milestone payment from partners Alvogen, Inc. and Lotus Pharmaceuticals
-- Elected nationally recognized attorney in highly regulated industries, and healthcare specialist, Janet Rehnquist, Esq., to the Company's Board of Directors
-- Management has taken actions to address NASDAQ listing compliance and naked shorting of NRx securities
-- Management to host a conference call, April 1, 2024, at 8:30 AM ET
RADNOR, Pa., April 1, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year ended December 31, 2023 and provided a business update.
"2023 was a pivotal year for NRx in which we advanced from a single clinical trial in a single indication to a dramatically streamline its operations with a 50% reduction in overhead costs, a 25% reduction in overall costs, and a $0.20 per share improvement in negative earnings, while completing our clinical trial objectives. We expect data from two key trials this month and predict our first commercial revenue by the end of 2024. Over the past year the Company has navigated the most challenging business environment in the history of the biotechnology industry. Despite unprecedented headwinds, we negotiated a critical commercial partnership for our lead compound in bipolar depression, while retaining rights to the far larger indications of chronic pain and PTSD," said Stephen Willard, J.D., Chief Executive Officer and Director of NRx Pharmaceuticals. "We augmented our intellectual property portfolio to include the use of our lead compound in chronic pain and anticipate results of a 200-person efficacy trial that could open a multibillion dollar opportunity in this therapeutic area. We have acquired sufficient data on safety and efficacy of ketamine to support a New Drug Application for IV ketamine in acute suicidality. We established the foundation of a specialty pharmaceutical business around ketamine that we expect to yield positive cash flow by the end of 2024. Finally, we received unanticipated data supporting the use of our lead compound to treat complicated Urinary Tract Infection and Pyelonephritis, a condition that affects 3 million Americans and results in more than 15,000 deaths annually. We believe that NRx is poised for substantial growth in 2024 and look forward sharing further results in our conference call."
Fourth Quarter Clinical, Regulatory and Corporate Highlights
Development of NRX-101 for Treatment-Resistant Suicidal Bipolar Depression
The Company has announced today that it expects data lock this week and release of top line data this month in its Phase 2b/3 trial of NRX-101 in Suicidal Bipolar Depression. In 2023, the Company published results of a phase 2 trial demonstrating that oral NRX-101 extends the effect of IV ketamine in reducing both suicidality and depression in patients presenting to the hospital. This trial is designed to determine whether oral NRX-101 can reduce depression and suicidality in outpatients, which would be a massive broadening of the potential market for the drug. This potential expansion was guided by the Company's January 2023 meeting with the FDA in which NRx was advised to seek approval for NRX-101 as a drug for bipolar depression as a chronic, intermittent disease, a far broader indication.
With the completion of data collection, an unprecedented data integrity standard (94% agreement between site raters and central raters) has been achieved across the completed cohort of patients.
In 2023, the Company completed manufacture and Chemical Manufacturing Controls for NRX-101. This initiative is expected to yield stability data sufficient to support a shelf life in excess of two years at time of potential drug launch (should the clinical trials be successful). The completion of this manufacturing milestone allowed the Company to decrease its ongoing expenditure associated with manufacturing and development of chemical manufacturing controls.
During Q4 and in early 2024, the Company has continued to solidify its working relationship with Alvogen and Lotus, and begun working in unison to plan the final development and commercialization of NRX-101. These partners recently advanced $5 million of the first milestone to the Company. As previously announced, a successful readout from this trial and FDA interaction will trigger an additional $4 million milestone payment together with transfer of future development costs to our partner. The partnership provides for potential milestones of $329 million and a royalty reaching 15% on Net Sales.
NRX-101 for Treatment of Chronic Pain:
The Company has previously detailed the scientific basis for treatment of chronic pain with DCS as outlined in a 2016 scientific paper published by Schnitzer, et. al. and in the White Paper posted by the Company's Scientific Leadership (Sappko, et. al.). In 2023, the Company licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain.
Chronic pain affects more than 50 million American adults, compared to the approximately 3 million who report thoughts of suicide on an annual basis. There has been no new non-opioid class of drugs to treat nociceptive pain in the past two decades and NRX-101 has the potential to be the first N-methyl-D-aspartate (NMDA)-antagonist drug to seek approval for this indication. Today, ketamine is used off label to treat nociceptive pain, despite its clear limitations (addiction, neurotoxicity, hallucination, and the need for IV administration.)
The Company is advised that data lock will occur this week in a 200-person randomized prospective trial funded by the US DOD (NCT 03535688) in which patients with chronic pain were randomly assigned to DCS 400mg/day vs. placebo. Top line results will follow. Should these results support efficacy of DCS in the treatment of chronic low back pain, they are expected to provide a Breakthrough Therapy path towards treatment of chronic pain with DCS and DCS-containing medicines.
Spin out of HOPE Therapeutics and progress towards an NDA for NRX-100 (ketamine) in the treatment of suicidal depression.
When NRx met with the FDA in January 2023, the agency strongly encouraged the Company to develop NRX-100 (IV Ketamine) as a labeled drug, rather than rely on prior stabilization of suicidality and depression achieved via the common clinical practice of infusing generic ketamine compounded in licensed pharmacies. Shortly thereafter, the FDA issued the first of two advisory letters warning physicians against using compounded forms of ketamine and began a program of rigorous inspections of such pharmacies. Although there was once an expectation that intranasal administration of ketamine would be effective in treating suicidality, the attempts to demonstrate the clinical efficacy of nasal racemic ketamine for acute suicidality have not succeeded.
Accordingly, in Q3 the Company finalized a scientific collaboration with Prof. Marion Leboyer of Paris, France and Prof. Mocrane Abbar of Lyon, France in order to incorporate the results of a 156-person inpatient trial of intravenous ketamine vs. placebo for the stabilization of patients admitted for acute suicidality (the KETIS trial). The findings of the trial demonstrate a statistically significant reduction in both suicidality (the primary endpoint) and depression (the secondary endpoint) among patients treated with intravenous ketamine compared to those treated with placebo. (Link)
In the fourth quarter, the company similarly licensed data from Columbia University. In this trial, Dr. Michael Grunebaum and colleagues demonstrated a rapid and statistically significant reduction in Suicidal Ideation (SSI) at day 1 (p=0.0003) and in depression (P=0.0234), as measured by the Profile of Mood States (POMS) among patients randomized to IV Ketamine compared to those randomized to midazolam. This trial was published in the American Journal of Psychiatry https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880701/.
The patient-level deidentified data from both studies have now been received by the Company and are being assembled in the electronic format required by the FDA. The Company believes that these randomized, blinded prospective trials encompassing nearly 240 participants, when submitted for review at a patient level could be sufficient to demonstrate preliminary safety and efficacy of intravenous ketamine in acutely suicidal patients. Data are expected to be transmitted to FDA by the end of 2Q23.
Submission of an NDA for the use of IV Ketamine is dependent upon submission of a manufacturing file documenting the manufacture of a presentation of ketamine suitable for single-patient use in the treatment of suicidal depression. In November 2023, the Company initiated manufacture of ketamine together with Nephron Pharmaceuticals, Inc. (West Columbia, SC) to develop a single patient presentation of ketamine. This formulation is expected to overcome some of the formulation deficiencies of existing forms of ketamine (developed for anesthesia) and is expected to have diversion-resistant and tamper-resistant features.
On March 30, 2024, the Company booked first commercial delivery of ketamine manufactured to 503b pharmacy standards from Nephron. HOPE will be distributing this presentation to qualified ketamine clinics in coordination with Nephron under Nephron's 503b pharmacy license in light of the current FDA-declared drug shortage of ketamine, starting this month (April 2024).
Treatment of Urinary Tract Infection (UTI) and Urosepsis:
Although treatment of UTI is quite different from use of NRX-101 to treat Central Nervous System disorders, D-cycloserine was originally developed as an antibiotic because of its role in disrupting the cell wall of certain pathogens. This is true of a number of drugs used in psychiatry today. D-cycloserine fell out of favor as an antibiotic in the 1970s because of the CNS effects caused by its NMDA-blocking properties and because of the widespread availability of effective first and second-generation antibiotics.
During Q3 2023, NRx tested NRX-101 and its components against resistant pathogens that appear on the Congressionally-mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRx was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA.
In recent years, increased antibiotic resistance to common pathogens that cause urinary tract infections and urosepsis (i.e., sepsis originating in the urinary tract) has resulted in a marked increase in cUTI, hospitalization, and death from urosepsis. The US Center for Disease Control and Prevention reports that more than 1.7 million Americans contract sepsis each year, of whom at least 350,000 die during their hospitalization or are discharged to hospice (CDC Sepsis Ref.). There are approximately 3 million patients per year who contract cUTI in the US annually (Lodise, et. al.). Additionally, should NRX-101 succeed in clinical trials, the Company will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
Qualification for QIDP affords a sponsor five years of additional market exclusivity from FDA, regardless of patent status.
The Company does not anticipate funding this initiative with core NRx assets and is exploring structures for partnership opportunities. Should the Company or its partners succeed in serving 10% of the cUTI market, the Company believes that the revenue from NRX-101 has the potential to hundreds of million annually, based on 3 million cases per year (Lodise, et. al.) in the US and potential pricing of over $3,500/course of therapy.
Cash runway and financing
The Company continues to believe cash on hand is sufficient to fund operations through potential delivery of the upcoming milestones described herein.
Financial Results for the Quarter and Year Ended December 31, 2023
For the three months ended December 31, 2023, we at NRx Pharmaceuticals reduced our net loss from $10.2 million in the final quarter of 2022 to $4.3 million in 2023, representing nearly a 60% improvement year over year. For that same period, we reduced research and development expenses from $4.5 million in 2022 to $2.5 million in 2023, while substantially improving and finalizing our clinical trial enrollment. The $2.0 million decrease is related primarily to a decrease of $1.1 million in clinical trial expenses, $0.6 million in stock-based compensation, and $0.2 million in consulting and personnel wage costs. Also in that 3 month period we recorded a 67% reduction in general and administrative expenses, from $5.4 million in 2022 to $1.8 million in 2023. The decrease of $3.6 million is related primarily to a decrease of $1.3 million in insurance expenses, $1.3 million in stock-based compensation, $0.5 million in employee expenses, $0.2 million in legal and professional consulting fees, and $0.2 million in franchise tax expenses.
For the year ended December 31, 2023, NRx Pharmaceuticals reduced its net loss to $30.2 million compared to $39.8 million in the prior year. These efficiencies represent an improvement in net loss of nearly $10.0 million year over and a 20 cent, or 34%, improvement in net loss per share year over year. Over that annual period we recorded $13.4 million of research and development expenses compared to $17.0 million for the same period in 2022 representing a 21% decrease year over year. The decrease of $3.6 is related primarily to a decrease of $2.1 million in clinical trial and development expenses, $0.9 million related to fees paid to regulatory and process development consultants, $0.8 million in stock-based compensation while offset by a $0.2 million increase in patent costs as our patent portfolio has expanded.
Please note that the improvement in G&A expenses is even larger than the improvement in other areas. We decreased G&A by $13.1 million, from $27.3 million in 2022 to $14.2 million in 2023, nearly a 50% decrease year over year.
As of December 31, 2023, we had $4.6 million in cash and cash equivalents. Over the first three months of 2024 we improved our access to working capital by $8 million total, representing $2.9 million from equity sales and $5.1 million from the Alvogen milestone advance, while reducing our corporate indebtedness by 50% as shown in our financial statements.
We continue to implement operational efficiencies to extend runway and focus on our path to generating revenue. We believe that the near-term delivery of clinical trial data and the planned the launch of HOPE Therapeutics will be defining events in the second quarter of 2024.
Conference Call and Webcast Details
A live webcast of the conference call will be available on the Company's website at 8:30 a.m. ET today, at https://ir.nrxpharma.com/events. An archive of the webcast will be available on the Company's website for 30 days. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-877-704-4453 or internationally 1-201-389-0920.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL76439&sd=2024-04-01 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-update-302104468.html
SOURCE NRx Pharmaceuticals, Inc.
Followers
|
1290
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
312737
|
Created
|
11/28/03
|
Type
|
Free
|
Moderator DAVE_007 | |||
Assistants mick WANG MaxPowerLove$Ihub fast.money $Pistol Pete$ |
UPDATE; 5-1-22
courtesy of charting /\ wit tweezer top calls /\ Tony
@Montana_Trades
Really good study sheet on Candlestick Patterns
[-chart]pbs.twimg.com/media/FRn8188XMAAdZvk?format=jpg&name=small[/chart]
01-15-2022
TRADING GIG
What the Fact (Factor) Column is:
The Factor is a proprietary indicator used for scanning in #DDAmanda.
It's defined as Today's $Traded divided by the average daily $Traded (20 day avg).
SO, if a stock has say a 10 Factor that day, it means she traded 10 Times the $ she normally trades.
That's significant, and many times indicates that a run in the stock is coming.
https://topnewsguide.com/
https://emerginggrowth.com/
CASH COW n. Slang: A steady dependable source of funds or income.... BYOB - Bring Your Own Buckets!
WELCOME!..we use chart TA and other scanning tools to catch those BIG MOOOO-VERS early!
Feel free to chime in anytime...Any stock is OK to discuss...
Make it your new home, if you'd like...
Let's make some MASSIVE BANK!
..
#66 _________________0
#65 ________________00
#64 _______________0000
#63 ___0__________000000___________0
#62 ___00_________000000___________0
#61 ____0000______000000__________00
#60 ____000000____0000000_____00000
#59 _0_____0000000_000000_00000000___0
#58 00______000000_00000_0000000____00
#57 0000_____000000_000_000000____0000
#56 _000000000__0000_0_000_0_000000000
#55 ____000000000__0_0_0_00000000000
#54 ________000000000000000000000
#53 ______________000_0_0000
#52 ____________00000_0__00000
#51 __________00______0_______00
#50 __________________0
#50 __________________0
#50 __________________0
#50 __________________0
#50 __________________0
LINKS;
http://nasdaqtrader.com/Trader.aspx?id=Calendar
FOR TRADING SHARE INFORMATION , DAILY OR PREVIOUS DAILY TRADING.
http://www.stratosphericstocks.com/stock-stats/
For Listed Stocks;
https://finviz.com/news.ashx
SmallCap Trading Techniques Smallcap Trading Techniques;
http://investorshub.advfn.com/boards/board.aspx?board_id=4203
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Posts Today
|
0
|
Posts (Total)
|
312737
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |